Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients

PHASE4TerminatedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Kidney TransplantationAnemiaVitamin D DeficiencyRenal Insufficiency, Chronic
Interventions
OTHER

High Hb target

"25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target."

DIETARY_SUPPLEMENT

cholecalciferol

1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.

Trial Locations (1)

565-0871

CANDLE Trial Study Group, Suita

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Chugai Pharmaceutical

INDUSTRY

collaborator

Japanese Society for the Promotion of Science

OTHER

collaborator

The Japan Kidney Foundation

OTHER

collaborator

Roche Diagnostics GmbH

INDUSTRY

lead

CANDLE-KIT Trial Study Group

OTHER